

**\*\*You are receiving this message as a VACP/VAVP enrolled provider contact of the Immunization Program\*\***

## **Beginning August 1<sup>st</sup>, MenQuadfi will replace Menactra as the only meningococcal A, C, W, Y conjugate vaccine (MenACWY) supplied by Sanofi.**

[Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020 | MMWR](#)

*"ACIP recommends routine vaccination with a quadrivalent meningococcal conjugate vaccine (MenACWY) for adolescents aged 11 or 12 years, with a booster dose at age 16 years. ACIP also recommends routine vaccination with MenACWY for persons aged  $\geq$  2 months at [increased risk](#) for meningococcal disease."*

### **State-supplied Meningococcal A, C, W, Y vaccines now include:**

- MenQuadfi (Sanofi) – Approved for 2 years and older (state-supplied through age 64)
- Menveo (GSK) – Approved for 2 months through 55 years

### **To be removed August 1<sup>st</sup>:**

- Menactra (Sanofi) – Approved for 9 months through 55 years

- 
- MenQuadfi will replace Menactra in practice catalogs automatically on August 1<sup>st</sup>.
  - This change does not impact practices that previously selected Menveo for Oct 2021 – Sept 2022 through the [vaccine choice process](#).
  - Use the existing inventory of Menactra at your practice before ordering MenQuadfi.
  - Practices in need of MenACYW vaccine for patients younger than age 2 can make a special request of Menveo by e-mailing [AHS.VDHImmunizationProgram@vermont.gov](mailto:AHS.VDHImmunizationProgram@vermont.gov), or leaving a comment in VIMS. See the [MenACWY Vaccine Recommendation by Age and Risk Factor](#) for guidance on when a request for Menveo is appropriate.

Any questions about this change can be sent to [AHS.VDHImmunizationProgram@vermont.gov](mailto:AHS.VDHImmunizationProgram@vermont.gov).

